Company Overview and News
In September 2017, I received slightly over $100K as a result of the commuted value of my pension plan. I decided to invest 100% of this money into dividend growth stocks. Each month I publish my results. I don't do this to brag, I do this to show you it's possible to build a portfolio during an all-time high market. The market will crash… eventually. In the meantime, I rather cash out on some juicy dividends!
VIG ANCUF ANCTF ENB FTS CGC ENB TWMJF V ATD.A ATD.B FTS WEED
In this article, we'll review all utilities in Canada that have increased their dividend for 5 or more years in a row and apply a dividend growth screen to try and find the best high-quality utility companies for further consideration. Turns out there was only one company that passed all of the criteria, but there are still a few other companies that are worthy of your consideration.
ACLTF CNUTF FTS EMRAF RNW VALU FTS TRI BIP CDUAF TRSWF CU
ST. JOHN’S, Terre-Neuve-et-Labrador, 04 mai 2018 (GLOBE NEWSWIRE) -- Fortis Inc. (« Fortis » ou la « Société ») (TSX:FTS) (NYSE:FTS) a annoncé les résultats des votes de son Assemblée générale annuelle des Actionnaires, qui se tenait aujourd’hui à Saint-Jean, Terre-Neuve-et-Labrador. Les Actionnaires ont voté en faveur de tous les points à l’ordre du jour avant l’assemblée, y compris pour l’élection des administrateurs nommés, la nomination de Deloitte LLP en tant qu’auditeurs de la Société et le vote consultatif visant à valider l’approche adoptée par la Société pour la rémunération de ses cadres supérieurs.
ST. JOHN'S, Newfoundland and Labrador, May 03, 2018 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX:FTS) (NYSE:FTS) announced the voting results from its Annual Meeting of Shareholders held today in St. John's, Newfoundland and Labrador. Shareholders voted in favour of all items of business before the meeting, including electing the nominated directors, appointing Deloitte LLP as the Corporation's auditors and voting on an advisory basis to accept the Corporation's approach to executive compensation.
ST. JOHN’S, Terre-Neuve-et-Labrador, 01 mai 2018 (GLOBE NEWSWIRE) -- Barry Perry, président et chef de la direction de Fortis Inc. (« Fortis » ou la « Société ») (TSX:FTS) (NYSE:FTS), a annoncé aujourd’hui la nomination de Jocelyn Perry au poste de vice-président directeur et chef des finances de Fortis à compter du 1er juin 2018. Karl Smith, actuel vice-président directeur et chef des finances, prendra sa retraite le 31 mai 2018 après plus de 30 ans chez Fortis.
Ladies and gentlemen, thank you for standing by. My name is Dan, and I will be your conference operator today. Welcome to the Fortis Q1, 2018 Conference Call and Webcast. During the call all participants will be in a listen-only mode. There will be a question-and-answer session following the presentation. [Operator Instructions]
Fortis Inc. ("Fortis" or the "Corporation") (TSX:FTS) (NYSE:FTS), a leader in the North American regulated electric and gas utility industry, released its first quarter results today. The Corporation reported first quarter 2018 net earnings of $323 million, or $0.77 per common share, and adjusted net earnings1 of $293 million, or $0.69 per common share.
ST. JOHN’S, TERRE-NEUVE-ET-LABRADOR, 25 avr. 2018 (GLOBE NEWSWIRE) -- Fortis Inc. (« Fortis » ou la « Société ») (TSX:FTS) (NYSE:FTS) publiera ses résultats financiers du premier trimestre de 2018 le mardi 1er mai 2018. Une téléconférence et une Webémission se tiendront le même jour à 8 h 30 (Heure de l’Est). Barry Perry, président et directeur général, ainsi que Karl Smith, vice-président exécutif et directeur financier, communiqueront les résultats financiers du premier trimestre de 2018.
ST. JOHN'S, NEWFOUNDLAND AND LABRADOR, April 24, 2018 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX:FTS) (NYSE:FTS) will release its first quarter 2018 financial results on Tuesday, May 1, 2018. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). Barry Perry, President and Chief Executive Officer, and Karl Smith, Executive Vice President, Chief Financial Officer, will discuss Fortis' first quarter 2018 financial results.
ST. JOHN'S, NEWFOUNDLAND AND LABRADOR--(Marketwired - April 2, 2018) - Fortis Inc. ("Fortis" or the "Corporation") (TSX:FTS) (NYSE:FTS) will release its first quarter 2018 financial results on Tuesday, May 1, 2018. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). Barry Perry, President and Chief Executive Officer, and Karl Smith, Executive Vice President, Chief Financial Officer, will discuss Fortis' first quarter 2018 financial results.
ST. JOHN'S, NEWFOUNDLAND AND LABRADOR--(Marketwired - March 26, 2018) - Fortis Inc. ("Fortis" or the "Corporation") (TSX:FTS) (NYSE:FTS) announced today that it has established an at-the-market equity program (the "ATM Program") that allows the Corporation to issue up to C$500,000,000 (or its U.S. dollar equivalent) of common shares (the "Common Shares") from treasury to the public from time to time, at the Corporation's discretion.
MS.PRI MS.PRK FTS MS.PRE DTK MS.PRF MS.PRG MS MS.PRA FTS
ST. JOHN'S, NEWFOUNDLAND AND LABRADOR--(Marketwired - March 22, 2018) - Fortis Inc. ("Fortis" or the "Corporation") (TSX:FTS)(NYSE:FTS) today announced the Wataynikaneyap Power project has reached a major milestone with the announcement of a funding framework among Wataynikaneyap Power, the Government of Canada and the Government of Ontario. The project will connect 17 remote First Nations communities in Northwestern Ontario to the main electricity grid through the construction of 1,800 kilometres ("km") of transmission lines.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:FTS / Fortis Inc on message board site Silicon Investor.
|Options Investing: Trading the FTSE 100 and UK Stock Benchma||PC Flowers u0026 Gifts.com,Inc - (Nasdaq - PCFG)|
|Tis the Season . . . Gifts||FIRST TEAM SPORTS-FTSP|
|Mutually Owned Thrifts||Gifts for online friend.|